CTS™ KnockOut™ SR XenoFree Medium
CTS™ KnockOut™ SR XenoFree Medium
Citas y referencias (5)
Gibco™

CTS™ KnockOut™ SR XenoFree Medium

El medio Gibco CTS KnockOut SR sin xenógenos, cuando se formula como medio completo, permite el crecimiento y la expansiónMás información
Have Questions?
Cambiar vistabuttonViewtableView
Número de catálogoCantidad
12618013500 mL
12618012100 mL
Número de catálogo 12618013
Precio (MXN)
-
Cantidad:
500 mL
El medio Gibco CTS KnockOut SR sin xenógenos, cuando se formula como medio completo, permite el crecimiento y la expansión de células madre embrionarias humanas (hESC) y células madre pluripotentes inducidas humanas (hiPSC) en un medio de cultivo celular que contiene solo proteínas recombinantes humanas o de origen humano, lo que facilita la transición de la investigación del hESC e hiPSC de sobremesa a la clínica.

La línea de productos CTS le permite reducir la carga de los reactivos clasificados durante su transición de la investigación a las aplicaciones clínicas.

El medio CTS KnockOut SR sin xenógenos no contiene componentes bovinos u otros no humanos derivados de animales. Además de la expansión y del mantenimiento de cultivos de células madre pluripotentes, el medio CTS KnockOut SR sin xenógenos se puede utilizar para estudios hESC⁄hiPSC de crioconservación, derivación y diferenciación.

Los productos Gibco CTS son de alta calidad y se suministran con documentación armonizada como certificados de análisis, certificados de origen y acceso a cartas de autorización de nuestros archivos principales sobre fármacos, según corresponda.

Para su uso en investigación o fabricación de productos basados en células, genes o tejidos. PRECAUCIÓN: no diseñado para la administración directa en seres humanos o animales.

Especificaciones
Tipo de célulaCélulas madre embrionarias (ESC), células madre pluripotentes inducidas (ISPC)
Para utilizar con (aplicación)Terapia celular, investigación clínica, investigación traslacional
FormatoFrasco
Calidad de fabricaciónBuenas prácticas de fabricación actuales para dispositivos médicos, 21 CFR Parte 820 e ISO 13485
Tipo de productoMedios para células madre
Cantidad500 mL
Condiciones de envíoHielo seco
ClasificaciónSin suero
FormularioLíquido
Serum LevelSin suero
EsterilidadEstéril con filtro
Unit SizeEach
Contenido y almacenamiento
Almacenar entre -5 y -20 °C, proteger de la luz

Preguntas frecuentes

What is CTS?

The Gibco Cell Therapy Systems (CTS) portfolio of cell and gene therapy products are GMP manufactured, safety tested, and backed by regulatory documentation to support your transition from discovery through clinical and commercial manufacturing. Through our CTS solutions, we are committed to helping customers streamline therapeutic development, minimize risk, and ease the burden on their quality systems. Learn more here.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Do you offer a medical device–grade of CTS KnockOut SR XenoFree Medium?

Yes, we do offer a Class II medical device–labeled CTS KnockOut SR XenoFree Medium in the USA and Canada only. Please contact us at custommedia@thermofisher.com to discuss if a medical device grade is required for your application.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

How do I characterize human embryonic stem ( ES) cells?

Human ES cells are generally characterized by their typical morphology (they grow as tightly packed clusters of small cells with high ratio of nucleus to cytoplasm); surface marker expression; RT-PCR detection of stem cell-specific gene expression (such as Oct3/4, Sox2, and Nanog); alkaline phosphatase staining, and telomerase activity assay. The most commonly used ES specific surface markers include stage-specific embryonic antigens SSEA-3 and SSEA-4 for human ES cells. Other ES-specific surface antigens also include TRA-1-60 and TRA-1-81. (Science 282:1145 (1998).

How are human embryonic stem (ES) cells derived?

Human ES cells are derived from human blastocyst inner cell masses, isolated by immunosurgery with rabbit antiserum to BeWO cells (a human trophoblast cell line) (Science 282:1145 (1998)).

What are ES cells?

Embryonic stem (ES) cells are derived from the early mammalian embryo and are capable of unlimited, undifferentiated proliferation in vitro while maintaining their potential to differentiate into a wide of range of adult tissues including germ cells. The pluripotency of the ES cells is normally demonstrated in vitro by inducing ES cells to differentiate into embryoid bodies and checking lineage-specific markers for differentiated cells in three body layers (endo, meso, and ectoderm), or injecting them into immunodeficient mice and determining the cell types produced in the teratomas.

Citations & References (5)

Citations & References
Abstract
CD133-enriched Xeno-Free human embryonic-derived neural stem cells expand rapidly in culture and do not form teratomas in immunodeficient mice.
Authors:Haus DL, Nguyen HX, Gold EM, Kamei N, Perez H, Moore HD, Anderson AJ, Cummings BJ
Journal:
PubMed ID:25082219
'Common methods for the generation of human embryonic-derived neural stem cells (hNSCs) result in cells with potentially compromised safety profiles due to maintenance of cells in conditions containing non-human proteins (e.g. in bovine serum or on mouse fibroblast feeders). Additionally, sufficient expansion of resulting hNSCs for scaling out or up ... More
An ECM-based culture system for the generation and maintenance of xeno-free human iPS cells.
Authors:Kim HT, Lee KI, Kim DW, Hwang DY
Journal:Biomaterials
PubMed ID:23153417
'Pluripotent stem cells (PSCs) including induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) have emerged as a promising source for treating incurable diseases. Problems that urgently need to be resolved before the clinical application include avoiding potential xenopathogenic transmission and immune rejection that may be caused by the ... More
Concise Review: Manufacturing of Pancreatic Endoderm Cells for Clinical Trials in Type 1 Diabetes.
Authors:Schulz TC,
Journal:
PubMed ID:26062982
'The cellular component of ViaCyte''s VC-01 combination product for type 1 diabetes, pancreatic endoderm cells (PEC-01) derived from CyT49 human embryonic stem cells, matures after transplantation and functions to regulate blood glucose in rodent models. The aims in manufacturing PEC-01 at scale are to generate a consistent and robust transplantable ... More
Generation of human-induced pluripotent stem cells by a nonintegrating RNA Sendai virus vector in feeder-free or xeno-free conditions.
Authors:Macarthur CC, Fontes A, Ravinder N, Kuninger D, Kaur J, Bailey M, Taliana A, Vemuri MC, Lieu PT,
Journal:Stem Cells Int
PubMed ID:22550511
The generation of induced pluripotent stem cells (iPSCs) from somatic cells has enabled the possibility of providing unprecedented access to patient-specific iPSC cells for drug screening, disease modeling, and cell therapy applications. However, a major obstacle to the use of iPSC for therapeutic applications is the potential of genomic modifications ... More
cGMP production of patient-specific iPSCs and photoreceptor precursor cells to treat retinal degenerative blindness.
Authors:Wiley LA, Burnight ER, DeLuca AP, Anfinson KR, Cranston CM, Kaalberg EE, Penticoff JA, Affatigato LM, Mullins RF, Stone EM, Tucker BA,
Journal:Sci Rep
PubMed ID:27471043
'Immunologically-matched, induced pluripotent stem cell (iPSC)-derived photoreceptor precursor cells have the potential to restore vision to patients with retinal degenerative diseases like retinitis pigmentosa. The purpose of this study was to develop clinically-compatible methods for manufacturing photoreceptor precursor cells from adult skin in a non-profit cGMP environment. Biopsies were obtained ... More